Longitudinal changes of CSF biomarkers in memory clinic patients

被引:109
作者
Bouwman, F. H.
van der Flier, W. M.
Schoonenboom, N. S. M.
van Elk, E. J.
Kok, A.
Rijmen, F.
Blankenstein, M. A.
Scheltens, P.
机构
[1] VU Med Ctr, Alzheimers Ctr, NL-1081 HV Amsterdam, Netherlands
[2] VU Med Ctr, Dept Neurol, NL-1081 HV Amsterdam, Netherlands
[3] VU Med Ctr, Dept Clin Chem, NL-1081 HV Amsterdam, Netherlands
[4] VU Med Ctr, Dept Clin Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands
关键词
D O I
10.1212/01.wnl.0000271375.37131.04
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: In Alzheimer disease ( AD), longitudinal changes of beta-amyloid(1-42) ( A beta(1-42)), tau, and phosphorylated tau at threonine 181 ( ptau-181) in CSF have been reported in small studies only. We evaluated the natural course of CSF biomarkers in patients with AD, subjective complaints, and mild cognitive impairment ( MCI). Methods: One hundred five patients ( 50 AD, 38 MCI, 17 subjective complaints) underwent two lumbar punctures, with a mean interval of 21 +/- 9 months. CSF levels of A beta(1-42), tau, and ptau-181 were measured. Results: CSF A beta(1-42) and tau levels showed main effects for both diagnosis and time ( all p < 0.05), with average increases of 47 +/- 72 and 49 +/- 143 pg/mL. The interaction terms were not significant, which implies a similar time effect for all diagnostic groups. CSF ptau-181 levels showed a main effect for diagnosis ( p = 0.01) but not for time ( p = 0.27, increase of 1.0 +/- 12 pg/mL). Conclusion: Levels of CSF beta-amyloid 1-42 and tau but not phosphorylated tau at threonine 181 increased over time in this memory clinic patient cohort with comparable change in all diagnostic groups. The cross-sectional difference between diagnostic groups, however, exceeded by far the longitudinal changes within individuals, suggesting that these biomarkers are not sensitive as markers of disease progression.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 33 条
[1]   A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease [J].
Aisen, P. S. ;
Saumier, D. ;
Briand, R. ;
Laurin, J. ;
Gervais, F. ;
Tremblay, P. ;
Garceau, D. .
NEUROLOGY, 2006, 67 (10) :1757-1763
[2]   Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].
Andreasen, N ;
Minthon, L ;
Vanmechelen, E ;
Vanderstichele, H ;
Davidsson, P ;
Winblad, B ;
Blennow, K .
NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8
[3]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680
[4]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[5]   Usefulness of longitudinal measurements of β-Amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders [J].
Bouwman, Femke H. ;
van der Flier, Wiesje M. ;
Schoonenboom, Niki S. M. ;
van Elk, Evert J. ;
Kok, Astrid ;
Scheltens, Philip ;
Blankenstein, Marinus A. .
CLINICAL CHEMISTRY, 2006, 52 (08) :1604-1606
[6]   Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment [J].
de Leon, MJ ;
DeSanti, S ;
Zinkowski, R ;
Mehta, PD ;
Pratico, D ;
Segal, S ;
Rusinek, H ;
Li, J ;
Tsui, W ;
Saint Louis, LA ;
Clark, CM ;
Tarshish, C ;
Li, Y ;
Lair, L ;
Javier, E ;
Rich, K ;
Lesbre, P ;
Mosconi, L ;
Reisberg, B ;
Sadowski, M ;
DeBernadis, JF ;
Kerkman, DJ ;
Harnpel, H ;
Wahlund, LO ;
Davies, P .
NEUROBIOLOGY OF AGING, 2006, 27 (03) :394-401
[7]  
DIMITRI G, 1994, CLIN CHEM, V40, P501
[8]   Global prevalence of dementia: a Delphi consensus study [J].
Ferri, CP ;
Prince, M ;
Brayne, C ;
Brodaty, H ;
Fratiglioni, L ;
Ganguli, M ;
Hall, K ;
Hasegawa, K ;
Hendrie, H ;
Huang, YQ ;
Jorm, A ;
Mathers, C ;
Menezes, PR ;
Rimmer, E ;
Scazufca, M .
LANCET, 2005, 366 (9503) :2112-2117
[9]  
FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198
[10]   Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease [J].
Galimberti, D ;
Schoonenboom, N ;
Scheltens, P ;
Fenoglio, C ;
Bouwman, F ;
Venturelli, E ;
Guidi, I ;
Blankenstein, MA ;
Bresolin, N ;
Scarpini, E .
ARCHIVES OF NEUROLOGY, 2006, 63 (04) :538-543